Emergent BioSolutions Reports Unregistered Equity Sales
Ticker: EBS · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $8, $9.8802, $15.7185 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, filing
Related Tickers: EBS
TL;DR
Emergent BioSolutions filed an 8-K for unregistered equity sales on Sept 17.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on September 17, 2024, reporting on unregistered sales of equity securities. The filing details transactions related to the company's equity, though specific details on the nature or value of these unregistered sales are not provided in this excerpt.
Why It Matters
This filing indicates potential equity transactions outside of public markets, which could have implications for share dilution or insider activity.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can sometimes signal financial distress or be used for strategic purposes, requiring further investigation.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- September 17, 2024 (date) — Date of earliest event reported
FAQ
What specific type of equity securities were sold?
The filing excerpt does not specify the type of equity securities involved in the unregistered sales.
What was the aggregate dollar amount of the unregistered equity sales?
The provided text does not contain information on the dollar amount of the unregistered equity sales.
Who were the purchasers of these unregistered equity securities?
The filing excerpt does not identify the purchasers of the unregistered equity securities.
Were these sales related to any specific company event or financing?
The filing excerpt does not provide context linking these unregistered sales to specific company events or financing activities.
What is the significance of reporting 'Unregistered Sales of Equity Securities' on an 8-K?
Reporting unregistered sales of equity securities on an 8-K is required when such sales occur and are not registered with the SEC, often indicating private placements or other non-public transactions.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-09-17 16:12:31
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
- $8 — s at a price per share of approximately $8.98, which was based on the volume weigh
- $9.8802 — es of Common Stock was determined to be $9.8802 per share, and the exercise price of th
- $15.7185 — es of Common Stock was determined to be $15.7185 per share. The Warrants are currently e
Filing Documents
- ebs-20240917.htm (8-K) — 26KB
- 0001367644-24-000158.txt ( ) — 149KB
- ebs-20240917.xsd (EX-101.SCH) — 2KB
- ebs-20240917_lab.xml (EX-101.LAB) — 22KB
- ebs-20240917_pre.xml (EX-101.PRE) — 13KB
- ebs-20240917_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: September 17, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer